Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04504240Phase 3Completed

Role of Famotidine in the Clinical Improvement of COVID-19 Patients.

Role: collaborator

NCT04678739Phase 3Completed

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

Role: lead

NCT04693026Phase 3Unknown

Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Role: lead

All 3 trials loaded